Literature DB >> 33452890

Bone Disease in CKD in Children.

Fernando Santos1,2, Lucas Díaz-Anadón3, Flor A Ordóñez3, Dieter Haffner4.   

Abstract

This manuscript discusses mineral and bone disorders of chronic kidney disease (MBD-CKD) in pediatric patients with special emphasis on the underlying pathophysiology, the causes and clinical profile of growth retardation, the alterations in the growth plate, the strategies to optimize growth and the medical recommendations for prevention and treatment.

Entities:  

Year:  2021        PMID： 33452890     DOI： 10.1007/s00223-020-00787-z

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  75 in total

Review 1.  Chronic kidney disease-mineral-bone disorder: a new paradigm.

Authors:  Sharon M Moe; Tilman Drüeke; Norbert Lameire; Garabed Eknoyan
Journal:  Adv Chronic Kidney Dis       Date:  2007-01       Impact factor: 3.620

Review 2.  Sclerostin: a new biomarker of CKD-MBD.

Authors:  Andreja Figurek; Merita Rroji; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

Review 3.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

Review 4.  Cardiovascular complications in children with chronic kidney disease.

Authors:  Rukshana Shroff; Donald J Weaver; Mark M Mitsnefes
Journal:  Nat Rev Nephrol       Date:  2011-09-13       Impact factor: 28.314

5.  Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure.

Authors:  D M Kates; D J Sherrard; D L Andress
Journal:  Am J Kidney Dis       Date:  1997-12       Impact factor: 8.860

Review 6.  Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.

Authors:  Mark R Hanudel; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

Review 7.  Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts.

Authors:  Pierre Delanaye; Jean-Claude Souberbielle; Marie-Hélène Lafage-Proust; Guillaume Jean; Etienne Cavalier
Journal:  Nephrol Dial Transplant       Date:  2013-07-17       Impact factor: 5.992

Review 8.  Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

Authors:  S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2010-12-24       Impact factor: 4.507

Review 9.  Epidemiology of chronic kidney disease in children.

Authors:  Jérôme Harambat; Karlijn J van Stralen; Jon Jin Kim; E Jane Tizard
Journal:  Pediatr Nephrol       Date:  2011-06-29       Impact factor: 3.714

10.  Chronic kidney disease in children.

Authors:  Francesca Becherucci; Rosa Maria Roperto; Marco Materassi; Paola Romagnani
Journal:  Clin Kidney J       Date:  2016-06-05
View more
  3 in total

Review 1.  The clinical relevance of native vitamin D in pediatric kidney disease.

Authors:  Sushmita Banerjee; Jayati Sengupta; Surupa Basu
Journal:  Pediatr Nephrol       Date:  2022-08-05       Impact factor: 3.651

2.  Growth hormone treatment in the pre-transplant period is associated with superior outcome after pediatric kidney transplantation.

Authors:  Celina Jagodzinski; Sophia Mueller; Rika Kluck; Kerstin Froede; Leo Pavičić; Jutta Gellermann; Dominik Mueller; Uwe Querfeld; Dieter Haffner; Miroslav Zivicnjak
Journal:  Pediatr Nephrol       Date:  2021-09-20       Impact factor: 3.651

Review 3.  Muscle and Bone Impairment in Infantile Nephropathic Cystinosis: New Concepts.

Authors:  Dieter Haffner; Maren Leifheit-Nestler; Candide Alioli; Justine Bacchetta
Journal:  Cells       Date:  2022-01-05       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.